FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143243043> ?p ?o ?g. }

• W2143243043 endingPage "563" @default.
• W2143243043 startingPage "551" @default.
• W2143243043 abstract "The purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous analysis (Glauser et al., 2006) to provide a comprehensive update. The prior analysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were analyzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations. This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat analysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs have been published. The combined analysis (1940–2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-analyses. New efficacy/effectiveness findings include the following: levetiracetam and zonisamide have level A evidence in adults with partial onset seizures and both ethosuximide and valproic acid have level A evidence in children with childhood absence epilepsy. There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for adults with partial onset seizures. Although ethosuximide and valproic acid now have level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general. These findings reinforce the need for multicenter, multinational efforts to design, conduct, and analyze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered." @default.
• W2143243043 created "2016-06-24" @default.
• W2143243043 creator A5002880520 @default.
• W2143243043 creator A5004263035 @default.
• W2143243043 creator A5015375196 @default.
• W2143243043 creator A5019416797 @default.
• W2143243043 creator A5025493981 @default.
• W2143243043 creator A5026925261 @default.
• W2143243043 creator A5038885649 @default.
• W2143243043 creator A5040883137 @default.
• W2143243043 creator A5061862920 @default.
• W2143243043 creator A5071831642 @default.
• W2143243043 date "2013-01-25" @default.
• W2143243043 modified "2023-10-17" @default.
• W2143243043 title "Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes" @default.
• W2143243043 cites W1491157696 @default.
• W2143243043 cites W1551261327 @default.
• W2143243043 cites W1599565459 @default.
• W2143243043 cites W1964366976 @default.
• W2143243043 cites W1965450907 @default.
• W2143243043 cites W1968691427 @default.
• W2143243043 cites W1973792829 @default.
• W2143243043 cites W1979566021 @default.
• W2143243043 cites W1979742136 @default.
• W2143243043 cites W1980415237 @default.
• W2143243043 cites W1981375790 @default.
• W2143243043 cites W1983021024 @default.
• W2143243043 cites W1984760496 @default.
• W2143243043 cites W1994457839 @default.
• W2143243043 cites W1995018101 @default.
• W2143243043 cites W2002407252 @default.
• W2143243043 cites W2002808263 @default.
• W2143243043 cites W2015221399 @default.
• W2143243043 cites W2017212385 @default.
• W2143243043 cites W2026750272 @default.
• W2143243043 cites W2027242474 @default.
• W2143243043 cites W2028500192 @default.
• W2143243043 cites W2030113059 @default.
• W2143243043 cites W2034278159 @default.
• W2143243043 cites W2037222801 @default.
• W2143243043 cites W2039674635 @default.
• W2143243043 cites W2040888683 @default.
• W2143243043 cites W2041504470 @default.
• W2143243043 cites W2045274557 @default.
• W2143243043 cites W2047200977 @default.
• W2143243043 cites W2056983769 @default.
• W2143243043 cites W2058147010 @default.
• W2143243043 cites W2059014274 @default.
• W2143243043 cites W2061631141 @default.
• W2143243043 cites W2063273170 @default.
• W2143243043 cites W2064482573 @default.
• W2143243043 cites W2064703133 @default.
• W2143243043 cites W2072923583 @default.
• W2143243043 cites W2075552514 @default.
• W2143243043 cites W2076662133 @default.
• W2143243043 cites W2077751878 @default.
• W2143243043 cites W2085059524 @default.
• W2143243043 cites W2086129924 @default.
• W2143243043 cites W2087388267 @default.
• W2143243043 cites W2095558066 @default.
• W2143243043 cites W2096742584 @default.
• W2143243043 cites W2097462102 @default.
• W2143243043 cites W2098517987 @default.
• W2143243043 cites W2114002180 @default.
• W2143243043 cites W2115659543 @default.
• W2143243043 cites W2116043268 @default.
• W2143243043 cites W2123177504 @default.
• W2143243043 cites W2123287446 @default.
• W2143243043 cites W2126685531 @default.
• W2143243043 cites W2132785864 @default.
• W2143243043 cites W2138521331 @default.
• W2143243043 cites W2147646629 @default.
• W2143243043 cites W2147974822 @default.
• W2143243043 cites W2156910631 @default.
• W2143243043 cites W2157291067 @default.
• W2143243043 cites W2162729385 @default.
• W2143243043 cites W2168915562 @default.
• W2143243043 cites W2320058521 @default.
• W2143243043 cites W2322086287 @default.
• W2143243043 cites W4246199030 @default.
• W2143243043 doi "https://doi.org/10.1111/epi.12074" @default.
• W2143243043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23350722" @default.
• W2143243043 hasPublicationYear "2013" @default.
• W2143243043 type Work @default.
• W2143243043 sameAs 2143243043 @default.
• W2143243043 citedByCount "582" @default.
• W2143243043 countsByYear W21432430432013 @default.
• W2143243043 countsByYear W21432430432014 @default.
• W2143243043 countsByYear W21432430432015 @default.
• W2143243043 countsByYear W21432430432016 @default.
• W2143243043 countsByYear W21432430432017 @default.
• W2143243043 countsByYear W21432430432018 @default.
• W2143243043 countsByYear W21432430432019 @default.
• W2143243043 countsByYear W21432430432020 @default.
• W2143243043 countsByYear W21432430432021 @default.
• W2143243043 countsByYear W21432430432022 @default.
• W2143243043 countsByYear W21432430432023 @default.
• W2143243043 crossrefType "journal-article" @default.

• next